Modular Medical
MODD

$2.26

0.44%

Market Cap: $73.6M

About: Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.

Employees: 40

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

3% more funds holding

Funds holding: 30 [Q1] → 31 (+1) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

1.71% less ownership

Funds ownership: 33.7% [Q1] → 31.99% (-1.71%) [Q2]

15% less capital invested

Capital invested by funds: $19.3M [Q1] → $16.4M (-$2.9M) [Q2]

25% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 8

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for MODD.

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about MODD published over the past 30 days

Modular Medical Announces Issuance of U.S. Patent Covering Key Aspects of Core Pumping Technology

Allowed claims cover major features of pumping mechanism in FDA-cleared MODD1 product SAN DIEGO, CA / ACCESSWIRE / September 18, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" thanks to its user-friendly and affordable design, announced the issuance of U.S. Divisional Patent Application No. 17/968,599.

Modular Medical Announces Issuance of U.S. Patent Covering Key Aspects of Core Pumping Technology

Modular Medical Announces Finalization of Protocol for GLP-1 Personalized Metabolic Therapy Study Utilizing the MODD1 Platform

-Proof of Concept Study in Rapid Acting GLP-1 to commence in October 2024 with data expected in November 2024 -Pre-clinical study to explore use of MODD1 pump as a personalized delivery system for people who discontinue long-acting GLP-1 formulations -CEO to discuss further details of the program in Tribe Public Webinar on Wednesday, September 11 at 8:30 a.m. Pacific time SAN DIEGO, CA / ACCESSWIRE / September 11, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" thanks to its user friendly and affordable design, today announced an update on its proof-of-concept study in a high-fat diet-induced obese ("DIO") mouse model to explore the potential future use of the MODD1 pump platform to assist patients who struggle with tolerability, inconsistent efficacy, and cost of long acting GLP-1 therapies.

Modular Medical Announces Finalization of Protocol for GLP-1 Personalized Metabolic Therapy Study Utilizing the MODD1 Platform

Registration Is Now Open For Tribe Public's Webinar Event "Diabetes, Obesity, GLP-1, & The MODD-1 Opportunity" Featuring Modular Medical CEO On Wednesday, September 11, 2024

Meet with Modular Medical CEO, Jeb Besser There are more than 3 million individuals who use daily insulin to help with the care of Diabetes in the US.100% of patient population require daily insulin injection. Only 20% currently use an insulin pump.

Registration Is Now Open For Tribe Public's Webinar Event "Diabetes, Obesity, GLP-1, & The MODD-1 Opportunity" Featuring Modular Medical CEO On Wednesday, September 11, 2024

Modular Medical Announces Conference Call to Discuss FDA Clearance of the MODD1 Insulin Pump

SAN DIEGO, CA / ACCESSWIRE / September 4, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch a market expansion product with a more accessible, easier to prescribe, and easier to pay for and live with technology, today announced it will hold a conference call and webcast tomorrow, Thursday, September 5, 2024, at 8:30 a.m. Eastern Time to discuss the U.

Modular Medical Announces Conference Call to Discuss FDA Clearance of the MODD1 Insulin Pump

Modular Medical Announces FDA Clearance of the MODD1 Insulin Pump

MODD1 is a patch pump for ALL adults with Type 1 and Type 2 diabetes Designed to be simpler and more affordable to expand access to diabetes technology for previously underserved communities Commercial availability expected in early 2025 SAN DIEGO, CA / ACCESSWIRE / September 4, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch a market expansion product with a more accessible, easier to prescribe, and easier to pay for and live with technology, today announced it has received U. S. Food and Drug Administration ("FDA") clearance to market and sell its MODD1 pump in the United States.

Modular Medical Announces FDA Clearance of the MODD1 Insulin Pump

Registration is Now Open for Tribe Public's Webinar Event "Diabetes Care Innovator Modular Medical Takes Next Steps" Featuring Modular Medical CEO on Friday, August 9, 2024

The global diabetes care market, valued at $18.9 billion in 2023, is projected to reach $35.8 billion by 2028 The insulin pump segment is expected to grow from $5.26 billion to $21.65 billion by 2032 Discover how Modular Medical is accelerating the development of technology to empower the whole diabetes community with MODD1 Meet with Modular Medical CEO Jeb Besser SAN DIEGO, CA / ACCESSWIRE / August 8, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced that Jeb Besser, CEO of Modular Medical, will present at Tribe Public's Webinar Presentation and Q&A Event titled "Diabetes Care Innovator Modular Medical Takes Next Steps." The Event is scheduled to begin at 8:30am pacific/11:30am eastern on Friday, August 9, 2024.

Registration is Now Open for Tribe Public's Webinar Event "Diabetes Care Innovator Modular Medical Takes Next Steps" Featuring Modular Medical CEO on Friday, August 9, 2024

Modular Medical Initiates Transfer of Manufacturing Operations to Phillips Medisize

SAN DIEGO, CA / ACCESSWIRE / August 7, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch the next generation of easy-to-use, prescribe and live with affordable insulin pump technology, today announced it has begun the transfer of its pilot line manufacturing operations to a Phillips Medisize manufacturing site in Queretaro, Mexico. Phillips Medisize, a Molex company, has been an outstanding collaborator in the development of Modular Medical's platform product, supply chain and manufacturing operations, as the Company intends to transition from pre-commercial production to high-volume device manufacturing.

Modular Medical Initiates Transfer of Manufacturing Operations to Phillips Medisize

Modular Medical Announces Proof-of-Concept Study for Personalized Metabolic Therapy utilizing the MODD1 Platform

Pre-clinical study to explore use of MODD1 pump as a delivery system for FDA-approved, short acting peptides, as a personalized alternative for people who discontinue long-acting GLP-1 formulations SAN DIEGO, CA / ACCESSWIRE / July 15, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced a proof-of-concept study with Gubra A/S ("Gubra") in a high-fat, diet-induced obese ("DIO") mouse model to explore the potential future use of the MODD1 pump platform to assist patients who struggle with tolerability, inconsistent efficacy, and cost of long acting GLP-1 therapies. "A recent study published by Blue Health Intelligence using data from a national dataset of private insurers found that about half of all patients prescribed a GLP-1 drug for weight loss discontinued after the first 12 weeks, with approximately 30% discontinuing in the first four weeks," commented Jeb Besser, Chief Executive Officer of Modular Medical.

Modular Medical Announces Proof-of-Concept Study for Personalized Metabolic Therapy utilizing the MODD1 Platform

Modular Medical Announces Addition to the Russell Microcap(R) Index

SAN DIEGO, CA / ACCESSWIRE / June 3, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced that it is set to join the Russell Microcap Index at the conclusion of the 2024 Russell indexes annual reconstitution, effective when the U.S. market opens on July 1, 2024. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes.

Modular Medical Announces Addition to the Russell Microcap(R) Index

Modular Medical Announces Steve Gemmell as New Vice President of Engineering

SAN DIEGO, CA / ACCESSWIRE / March 26, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced the addition of Steve Gemmell as Vice President of Engineering. Gemmell has over 20 years of experience in medical device product development and operations and previously held R&D leadership positions with Cytrellis Biosystems, Inc., Onduo, a joint venture between Sanofi SA and Verily Life Sciences, and Insulet Corporation.

Modular Medical Announces Steve Gemmell as New Vice President of Engineering

See News Rankings